Antibiotic drug resistance TB in India

Gohil, Chiragkumar J.; Patel, Priyanka R.; Gohil, Jignakumari J.

doi:10.18231/j.ijpca.2021.028

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to mutation in Mycobacterium genomes and other structural changes in it can resist the typical inhibitory medicines. 2 The emergence of resistance has complicated illness management strategies and treatment, particularly when a patient also co-infected HIV. Tubercle bacillus genetic mutant selection plays a critical part in the emergence and development of the resistant strain.…”

Section: Introductionmentioning

confidence: 99%

Mechanism and management of antibiotic drug resistance tuberculosis

Gohil

Parmar²,

Patel³

et al. 2022

IJPCA

Self Cite

View full text Add to dashboard Cite

Drug resistance in tuberculosis has been shown to result from spontaneous mutation in several chromosomal genes of M.Tuberculosis. Mutation may reduce the medications' capacity to bind to the target genes. In many patients polydrug resistance, multidrug resistance, rifampicin resistance (RR) and extensive drug resistance (XDR) were seen. The diagnosis of drug-resistant TB in HIV-positive persons is more difficult and may be confused with other pulmonary or systemic infections. Management of patients with mono- or poly-resistant TB will be done with standard first line chemotherapy. Treatment of latent infection for people suffering from multidrug resistant bacilli is problematic because the only cure by isoniazid and rifampicin. In the recent cases of severe hepatotoxicity associated with preventive treatment comprising either pyrazinamide and rifampicin or pyrazinamide and fluoroquinolone. The use of dilatory fluoroquinolones, such as moxifloxacin, remarkable improved treatment outcomes of XDR-TB.

show abstract

Section: Introductionmentioning

confidence: 99%